Immediate Impact
20 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Development of NK cell-based cancer immunotherapies through receptor engineering
2024 Standout
Works of Jane Estell being referenced
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
2023
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jane Estell | 171 | 119 | 26 | 129 | 16 | 207 | |
| Wolney Barreto | 155 | 106 | 14 | 125 | 10 | 194 | |
| Daniel Morillo | 148 | 138 | 66 | 93 | 27 | 262 | |
| Katarina Uttervall | 190 | 116 | 26 | 120 | 24 | 213 | |
| Roberta Gonella | 79 | 114 | 36 | 60 | 17 | 254 | |
| Francesca Bonello | 138 | 102 | 27 | 101 | 18 | 175 | |
| M.D. Minden | 82 | 52 | 23 | 150 | 16 | 284 | |
| Kallappa M. Koti | 88 | 133 | 11 | 159 | 14 | 283 | |
| Carly Campbell | 82 | 70 | 33 | 201 | 18 | 293 | |
| Hartmut Kristeleit | 73 | 114 | 36 | 88 | 18 | 224 | |
| Michael Leisch | 73 | 72 | 13 | 111 | 13 | 261 |
All Works
Loading papers...